MiMedx MDXG
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 14th percentile, 5-year average -13.0x
#2799 of 2972 stocks by PE (1 = cheapest)
Around its usual level · 45th percentile, 5-year average 263.9x
#3531 of 5311 stocks by PB (1 = cheapest)
Below its usual level · 30th percentile, 5-year average 2.4x
#2415 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.68 | – | 263.91 | 45% (cheaper than usual) | #3531 of 5311 (1 = cheapest) |
| PE | -29.85 | -99.62 | -13.02 | 14% (cheaper than usual) | #2799 of 2972 (1 = cheapest) |
| PS | 1.86 | 2.06 | 2.45 | 30% (cheaper than usual) | #2415 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on MDXG.
Sign in to join the discussion.